EID1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human cervical adenocarcinoma (HeLa) cells with targeted disruption of the EID1 gene. This knockout model abolishes expression of the endogenous EID1 protein, a cellular inhibitor of the histone acetyltransferases EP300 and CREBBP. The polyclonal format, derived from non-clonal selection of edited cells, provides a heterogeneous pool of genotypes that minimizes clonal artifacts and enables robust loss-of-function analysis. Researchers can utilize this model to investigate the consequences of releasing EP300/CREBBP repression on chromatin modification and gene expression.
HeLa is an immortalized epithelial cell line originally derived from a cervical adenocarcinoma of Henrietta Lacks. Widely employed in cancer biology, virology, and gene expression studies, HeLa cells exhibit a fully transformed phenotype characterized by aneuploidy, rapid proliferation, and high transfectability. In the context of EID1 knockout, HeLa offers a cancer-relevant background for examining the interplay between histone acetylation dynamics, cell cycle regulation, and differentiation blockade. The cell line??s well-annotated genome and epigenome facilitate detailed mechanistic studies.
EID1 (EP300-interacting inhibitor of differentiation 1) directly binds EP300 and CREBBP to suppress their histone acetyltransferase activity, thereby repressing transcription of differentiation-associated genes and promoting cell cycle progression. EID1 functions downstream of TGF-?? signaling, where it interacts with the transcription factors SMAD2 and SMAD3, integrating growth factor cues with epigenetic control. Additionally, EID1 associates with nuclear receptors, further modulating transcriptional outputs. Consequently, disruption of EID1 is anticipated to relieve inhibition of EP300/CREBBP, leading to increased histone acetylation marks and altered expression of genes involved in differentiation and cell fate decisions.
In the HeLa cellular environment, EID1 knockout creates a powerful system to dissect the molecular links between histone acetylation and malignant phenotypes. Since EID1 normally blocks differentiation, its loss may partially reactivate differentiation programs, providing a model to study the reversal of cancer-associated dedifferentiation. Researchers can explore how EID1 depletion reshapes TGF-?? signaling, histone modification landscapes, and cell cycle profiles. This polyclonal population is particularly valuable for assessing heterogeneous responses to epigenetic perturbations, reflecting the complexity of tumor cell populations.
This knockout model is suited for a wide array of experimental approaches. Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) enables mapping of histone acetylation changes at specific genomic loci, while western blotting and immunofluorescence detect global acetyl-histone H3 levels. Reporter assays quantify EP300/CREBBP transcriptional activity, and co-immunoprecipitation confirms disrupted protein interactions. Transcriptomic profiling via RNA-seq and targeted RT-qPCR reveals alterations in differentiation markers and downstream target genes. Flow cytometry monitors cell cycle distribution, and immunofluorescence visualizes acetyl-histone distribution. These polyclonal cells also serve as a platform for epigenetic drug screening. For further information or custom requests, please contact Ascent Research.
